GOLD 2023 update: implications for clinical practice
DR Tamondong-Lachica, N Skolnik… - … Journal of Chronic …, 2023 - Taylor & Francis
In 2022, over 3 million people died of chronic obstructive pulmonary disease (COPD) and
the global burden of the disease is expected to increase over the coming decades …
the global burden of the disease is expected to increase over the coming decades …
Clinical Management of COPD in the Real World: Can Studies Reveal Errors in Management and Pathways to Improve Patient Care?
DMG Halpin - Pragmatic and Observational Research, 2023 - Taylor & Francis
Real world data comprise information on health care that is derived from multiple sources
outside typical clinical research settings. This review focuses on what real world evidence …
outside typical clinical research settings. This review focuses on what real world evidence …
Relationship of COPD exacerbation severity and frequency on risks for future events and economic burden in the Medicare fee-for-service population
S Sethi, BJ Make, SB Robinson, S Kumar… - … Journal of Chronic …, 2022 - Taylor & Francis
Purpose To quantify the effects of moderate and/or severe chronic obstructive pulmonary
disease (COPD) exacerbations on future exacerbations and healthcare costs in Medicare …
disease (COPD) exacerbations on future exacerbations and healthcare costs in Medicare …
Quality standard position statements for health system policy changes in diagnosis and management of COPD: a global perspective
Introduction Despite being a leading cause of death worldwide, chronic obstructive
pulmonary disease (COPD) is underdiagnosed and underprioritized within healthcare …
pulmonary disease (COPD) is underdiagnosed and underprioritized within healthcare …
[HTML][HTML] Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines Reviewed
M Sharma, S Joshi, P Banjade… - The Open Respiratory …, 2024 - ncbi.nlm.nih.gov
Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines Reviewed -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
Pharmaceutical treatment status of patients with COPD in the community based on medical Internet of Things: a real-world study
P Wu, Y Jiang, F Si, H Wang, X Song… - NPJ Primary Care …, 2024 - nature.com
This study aimed to investigate the real-world standardisation and adherence of medical
treatment regimens in patients with chronic obstructive pulmonary disease (COPD) in the …
treatment regimens in patients with chronic obstructive pulmonary disease (COPD) in the …
Increased herpes zoster risk with inhaled corticosteroid use for those with chronic obstructive pulmonary disease
BP Yawn, E Callen, G Gaona-Villarreal… - … : Journal of the …, 2024 - pmc.ncbi.nlm.nih.gov
Methods To test the hypothesis that a longer duration of an ICS as part of COPD therapy is
associated with increased HZ risk using real-world data from the DARTNet Practice …
associated with increased HZ risk using real-world data from the DARTNet Practice …
Costs and clinical consequences of compliance with COPD GOLD recommendations or national guidelines compared with current clinical practice in Belgium …
S Sethi, A Wright, ES Hartgers-Gubbels… - … Journal of Chronic …, 2022 - Taylor & Francis
Purpose The objective of this study was to assess the clinical and cost benefits of treating
patients with chronic obstructive pulmonary disease (COPD) according to global and …
patients with chronic obstructive pulmonary disease (COPD) according to global and …
Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate …
Background ATS and GOLD guidelines recommend treating low-exacerbation risk COPD
patients with dual (LAMA/LABA) agents and reserving triple therapy (TT; LAMA/LABA and …
patients with dual (LAMA/LABA) agents and reserving triple therapy (TT; LAMA/LABA and …
Pulmonary outcomes of incretin-based therapies in COPD patients receiving single-inhaler triple therapy
Introduction Patients with chronic obstructive pulmonary disease (COPD) on triple therapy
often face exacerbations and comorbidities. Emerging evidence suggests that glucagon-like …
often face exacerbations and comorbidities. Emerging evidence suggests that glucagon-like …